Journal article
Reducing hyperglucagonemia in type 2 diabetes using low dose Glibenclamide: results of the LEGEND-A pilot study
- Abstract:
-
Fasting hyperglucagonemia is a key feature of type 2 diabetes (T2D), which leads to increased hepatic glucose production and exacerbates hyperglycemia. Preclinical studies have shown that low concentrations of sulfonylureas can partially restore appropriate glucose-regulated glucagon secretion in islets from donors with T2D. In this pilot clinical trial, sixteen participants with T2D (diet controlled or on metformin alone) underwent a 4-week open-label, non-randomized, dose-titration (0.3–6mg...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Authors
Bibliographic Details
- Publisher:
- Wiley Publisher's website
- Journal:
- Diabetes, Obesity and Metabolism Journal website
- Volume:
- 24
- Issue:
- 8
- Pages:
- 1671-1675
- Publication date:
- 2022-05-18
- Acceptance date:
- 2022-04-28
- DOI:
- EISSN:
-
1463-1326
- ISSN:
-
1462-8902
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
1255584
- Local pid:
- pubs:1255584
- Deposit date:
- 2022-05-04
Terms of use
- Copyright holder:
- Spiliotis et al
- Copyright date:
- 2022
- Rights statement:
- © 2022 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record